Although Janus kinase (JAK) inhibitor therapy does not specifically or fully block IFN-β or constitutively activated STING, it does inhibit type I and II IFN signaling [32] and several reports have noted clinical improvement in SAVI with decreased skin vasculopathy and stabilization of lung disease on JAK inhibitor therapy [20, 33]. The gene discussed is SGCG; the disease is STING-associated vasculopathy with onset in infancy.